Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ESMO
Filter by Topic
ESMO 2010 Conference
ESMO 2011 Conference
ESMO 2012 Conference
ESMO 2013 Conference
ESMO 2014 - Gastrointestinal and Head & Neck Cancer
ESMO 2014 - Immuno-Oncology
ESMO 2014 - Prostate Cancer
ESMO 2014 Highlights
ESMO 2016
ESMO 2017 Highlights
ESMO 2018
ESMO 2019
Positive Data Continue to Accrue for Crizotinib in ALK-Positive NSCLC
By
Caroline Helwick
ESMO
,
ESMO 2011 Conference
October 2011, Vol 2, No 6
Read Article
Value of Bevacizumab in Ovarian Cancer Got a Boost in a New Analysis
By
Caroline Helwick
ESMO
,
ESMO 2011 Conference
October 2011, Vol 2, No 6
Stockholm, Sweden—The indefinite use of bevacizumab (Avastin) in patients with re lapsed ovarian cancer got another boost at the 2011 European Multi disciplinary Cancer Congress, with a subanalysis of the phase 3 OCEANS trial showing consistent benefit across subgroups.
Read Article
Pemetrexed Plus Bevacizumab Maintenance Keeps NSCLC at Bay Longer
By
Caroline Helwick
ESMO
,
ESMO 2011 Conference
October 2011, Vol 2, No 6
Stockholm, Sweden—Two expensive drugs may be better than 1 for maintenance treatment of advanced non– small-cell lung cancer (NSCLC), according to a study at the 2011 European Multidisciplinary Cancer Congress.
Read Article
New Bone-Targeting Compound Improves Survival in Metastatic Prostate Cancer
By
Caroline Helwick
ESMO
,
ESMO 2011 Conference
October 2011, Vol 2, No 6
Stockholm, Sweden—An investigational alpha-pharmaceutical not only prevented skeletal-related events (SREs) in patients with prostate cancer with bone metastases in a phase 3 study presented at the 2011 European Multidisciplinary Cancer Congress, but it also improved overall survival.
Read Article
Therapy-Associated Complications Significantly Increase Cost of Cancer Care
By
Caroline Helwick
ESMO
,
ESMO 2011 Conference
October 2011, Vol 2, No 6
Stockholm, Sweden—The cost of cancer therapies is a growing concern not only for patients but also for providers and payers. Addressing the cost burden for those involved in cancer care is becoming a priority that cannot be avoided with the growing role of targeted therapies in oncology.
Read Article
The Road to Personalized Medicine Is Strewn with Obstacles
By
Audrey Andrews
ESMO
,
ESMO 2011 Conference
October 2011, Vol 2, No 6
Stockholm, Sweden—With recognition of common tumor mutations and a pipeline full of biologic agents that target them, personalized medicine should be all but a fait accompli. But one expert told attendees at the European Society for Medical Oncology’s 2011 European Multidisciplinary Cancer Congress, “We may be overpromising our patients.”
Read Article
Benefit to Longer Chemotherapy in Metastatic Breast Cancer
By
Charles Bankhead
ESMO 2010 Conference
,
ESMO
November/December 2010, Vol 1, No 6
Milan—Continuing first-line chemotherapy for metastatic breast cancer until disease progression significantly improves overall (OS) and progression free survival (PFS), according to a meta-analysis reported at the 35th ESMO Congress.
Read Article
High Cost to Managing Colorectal Cancer Toxicities
By
Caroline Helwick
ESMO 2010 Conference
,
ESMO
November/December 2010, Vol 1, No 6
Milan—Because the toxicity profiles for the 3 monoclonal antibodies used in treating metastatic colorectal cancer (mCRC) differ, there are substantial differences in the cost of treating side effects, according to research presented at the 35th ESMO Congress.
Read Article
Significant Impact for New Prostate Cancer Therapy
By
Charles Bankhead
ESMO 2010 Conference
,
ESMO
November/December 2010, Vol 1, No 6
Milan—Men with castration-resistant prostate cancer (CRPC) gained 4 months in overall survival (OS) when treated with the novel antiandrogen abiraterone acetate, data from a large randomized trial showed.
Read Article
Page 8 of 8
1
2
3
4
5
6
7
8
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma